This refresh
Data-driven refresh August 4, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,226 tickers); 1,791 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.6
Health Information Services · price $21.89 · 1Y $24.61 · 5Y $36.03 · 10Y $53.45
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.3x B+ · PEG 0.59 A-
Why now. DOCS’s AI‑driven workflow tool Ask is turning the platform into a daily clinical indispensable, fueling a 13.1% YoY revenue growth while preserving a 30.4% profit margin that powers a PEG of 0.59. The combination of sticky physician usage and premium ad spend from pharma creates a compounding engine that will keep earnings expanding well beyond the next quarter.
Moat. The Doximity network locks in U.S. physicians through HIPAA‑compliant tools like Ask and Scribe, making migration costly and preserving a captive audience for high‑margin sponsored content; this high‑frequency usage underpins a ROE of 20.6%, reflecting pricing power from category leadership in professional medical media.
Risk. The market is pricing DOCS for near‑term optimism: a forward P/E of 22.3 and a beta of 1.21 suggest elevated expectations, yet the Bull Rankings reverse‑DCF only assumes a 2% annual free‑cash‑flow growth versus the actual 13.1% revenue expansion, meaning a slowdown or margin compression would quickly invalidate the thesis. A sustained drop in ad spend or a rival platform siphoning user attention would trigger a sharp re‑rating.
Horizon. 1-3 yr $24.61 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $36.03 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.45 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89
Software - Application · price $257.49 · 1Y $269.61 · 5Y $394.73 · 10Y $585.56
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 14.7x A- · PEG 0.68 A-
Why now. Adobe’s Digital Experience platform is the engine behind its 11.5% YoY revenue growth, powered by a $10.3B free‑cash‑flow yield that fuels aggressive buybacks; its 28.7% profit margin and 62.8% ROE show pricing power in the enterprise‑grade marketing tech space—this is the single driver that makes owning ADBE compelling right now.
Moat. Adobe’s subscription‑based Digital Experience suite locks in marketers, agencies, and publishers through deep integration and data‑driven workflows that raise switching costs; the platform’s analytics‑to‑commerce stack creates a network effect where each new customer adds value to the ecosystem, making rapid imitation costly.
Risk. The high beta of 1.4 and a P/E of 14.7 suggest market volatility; if the 11.5% revenue growth stalls, the 28.7% margin could compress, and a debt‑to‑equity of 0.61 could pressure cash flow—this would erode the buyback engine that underpins the bull case.
Horizon. 1-3 yr $269.61 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $394.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $585.56 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 88.6
Software - Infrastructure · price $15.30 · 1Y $18.25 · 5Y $26.72 · 10Y $39.64
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.9x B+ · PEG 0.51 A-
Why now. DLocal’s pay‑in platform for global merchants is exploding, delivering 46.6% YoY revenue growth, a healthy 18% profit margin and a staggering 34.6% ROE. Our Bull Rankings model rates its Growth pillar at 100, driving an overall Quality‑Growth score of 88.6, which tells us the business is a high‑quality compounder. The thesis rests on the continued expansion of cross‑border e‑commerce and platform payments, where DLocal’s integrated suite of cards, bank transfers and alternative payment methods creates a self‑reinforcing loop of volume and pricing power.
Moat. The moat lives in DLocal’s end‑to‑end pay‑in and pay‑out stack that supports hundreds of alternative payment methods, locking merchants into a single integration for every market. This creates high switching costs and lets DLocal command pricing power, evident in its 34.6% ROE, far above sector averages. The platform’s ability to serve diverse verticals—from streaming to ride‑hailing—means revenue is sourced from a broad, sticky customer base that competitors can’t replicate quickly.
Risk. The reverse DCF shows the market is pricing in a -7% annual free‑cash‑flow growth for the next decade, a stark contrast to the 46.6% revenue surge we see now; this optimism may be overblown if cross‑border volumes soften. At a forward P/E of 23.9, the stock trades at a premium that could compress if growth decelerates or margins erode. A slowdown in APM adoption or a pricing squeeze would push the P/E higher and validate the bear case, breaking the compounding narrative.
Horizon. 1-3 yr $18.25 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.72 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $39.64 if current growth sustains into durable earnings power.
4. PGY — Pagaya Technologies Ltd. · score 88.5
Software - Infrastructure · price $21.92 · 1Y $28.50 · 5Y $41.73 · 10Y $61.90
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 15.5x A- · PEG 0.05 A
Why now. Pagaya’s Decline Monetization platform is unlocking a hidden pool of credit by automatically routing rejected loan applications to its AI‑driven network, fueling a revenue surge of 25.6% YoY while delivering a healthy 9.1% profit margin and generating $252 m of free cash flow. The Bull Rankings model awards an 88.5/100 quality‑growth score, with Growth as its strongest pillar, confirming that the business’s compounding engine is real and durable. The thesis hinges on scaling this AI‑powered monetization across more U.S. lenders, which should keep revenue expanding at double‑digit rates.
Moat. The moat lies in Pagaya’s proprietary AI that powers Decline Monetization and Dual Look, creating a data‑rich, network‑effect ecosystem where lenders rely on Pagaya’s predictive models to recover value from otherwise lost loans. Switching costs are high because partners embed Pagaya’s APIs into their underwriting pipelines, and the firm’s unique data set cannot be replicated quickly, underpinning its near‑20% ROE.
Risk. A bear‑case points to the stock’s extreme volatility (beta 5.37) and a debt‑to‑equity of 1.34, which could strain cash flow if growth stalls, while the reverse‑DCF implies a -14% annual free‑cash‑flow growth rate—far below the 25.6% revenue growth reality—suggesting the market may already be pricing in unsustainable optimism. A sustained slowdown in loan‑originations or a loss of key lender contracts would validate this risk and crush the upside.
Horizon. 1-3 yr $28.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $41.73 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $61.90 if current growth sustains into durable earnings power.
5. INTU — Intuit Inc. · score 87.8
Software - Application · price $323.60 · 1Y $454.65 · 5Y $665.66 · 10Y $987.46
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 19.7x B+ · PEG 0.82 B+
Why now. Intuit’s QuickBooks ecosystem is a cash‑flow engine, delivering 15.1% YoY revenue growth, 21.9% profit margin and a stellar 22.2% ROE that fuels compounding earnings; the Bull Rankings model scores Growth at 95, making the growth pillar the strongest driver. Coupled with a dividend raise and a market‑cap of $88.5B at a reasonable PE of 19.7, the stock is primed to ride the SMB finance wave. The thesis rests on the relentless expansion of QuickBooks and Mailchimp cross‑sell, which should keep the compounding engine humming.
Moat. QuickBooks and Mailchimp create a sticky, integrated platform for small‑ and mid‑market businesses, locking in users through data‑driven workflow automation and payroll‑to‑marketing synergies that are costly to replicate. This lock‑in underpins the 22.2% ROE, as Intuit can command pricing power and upsell financing services without significant competitive friction.
Risk. The market is pricing INTU for a reverse‑DCF implied free‑cash‑flow contraction of –4% annually, far below the actual 15.1% revenue growth, suggesting investors fear a slowdown; a dip in SMB spending or a successful rival offering a cheaper accounting suite could force growth toward that pessimistic path. A breach of the 19.7 PE multiple or a missed dividend hike would confirm the bear case.
Horizon. 1-3 yr $454.65 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $665.66 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $987.46 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 87.3
Education & Training Services · price $80.45 · 1Y $92.52 · 5Y $135.45 · 10Y $200.94
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 12.6x A- · PEG 0.45 A
Why now. Stride’s end‑to‑end virtual‑school platform is locking in a growing share of the U.S. public‑school market, and that stickiness fuels a compounding earnings engine. The business is delivering 10.9% revenue growth YoY while maintaining a healthy 12.2% profit margin and generating $414 m of free cash flow at a PEG of just 0.45, meaning earnings are scaling faster than the market expects. The thesis rests on continued enrollment expansion in blended and fully online districts, which should keep the free‑cash‑flow runway expanding year after year.
Moat. Stride’s integrated suite of curriculum, enrollment, progress‑tracking and support services creates a high‑switching‑cost ecosystem for districts that have already invested in its technology stack and professional services. This lock‑in, combined with an ROE of 18.8% driven by pricing power in the niche of virtual public schools, gives the company a durable advantage that rivals cannot replicate quickly.
Risk. The Bull Rankings model flags an implied -11% annual free‑cash‑flow growth over the next decade, a stark mismatch with the current 10.9% revenue expansion and suggests the market is pricing in unsustainable optimism; any slowdown in district funding for online programs would force the FCF trajectory toward that negative path and crush the valuation. A bear would watch for a dip in the P/E of 12.6 or a contraction in profit margin below 10% as the first warning sign.
Horizon. 1-3 yr $92.52 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $135.45 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $200.94 if current growth sustains into durable earnings power.
7. NBIX — Neurocrine Biosciences, Inc. · score 87.1
Drug Manufacturers - Specialty & Generic · price $166.06 · 1Y $211.94 · 5Y $310.30 · 10Y $460.32
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 24.2x B · PEG 0.47 A
Why now. The thesis hinges on Orilissa’s dominant position in endometriosis, a market projected to grow as more women seek effective therapy. NBIX’s revenue is up 34.4% YoY, free‑cash‑flow is $870 m, and the company trades at a modest 24.2× TTM P/E—well below the 10‑year implied 10% FCF growth of our Bull Rankings model. The combination of a 100‑point Growth pillar and a 20.9% profit margin means the company is a high‑quality compounder that can sustain 12% annual returns for a decade.
Moat. Orilissa’s 12‑month treatment cycle creates high switching costs for patients and payers, while the company’s 20.9% profit margin reflects pricing power from its category leadership in endometriosis. The 81‑point Quality pillar, driven by a 19.1% ROE, shows that NBIX can translate sales into shareholder value faster than peers, protecting its margins against generic entry.
Risk. The bear case centers on the 24.2× P/E, which presumes a 10% FCF growth that is 24% below the current 34.4% revenue growth—an optimistic assumption that could backfire if the endometriosis market saturates or if a competitor launches a cheaper alternative. A rise in debt‑to‑equity or a margin squeeze would erode the 20.9% profit margin that underpins the bull thesis, confirming the bear narrative.
Horizon. 1-3 yr $211.94 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $310.30 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $460.32 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 86.2
Semiconductors · price $211.94 · 1Y $302.83 · 5Y $443.37 · 10Y $657.71
FCF $119.1b A · Rev +70.7% A · D/E 0.07 B+ · P/E 32.5x B · PEG 0.55 A-
Why now. NVDA’s AI‑accelerated data‑center GPUs are driving a 70.7% YoY revenue surge, backed by a 63% profit margin and a 81.7% ROE that our model flags as a 100/100 growth pillar; the company’s $119.1B free‑cash‑flow and $5.1T market cap confirm it can monetize this momentum. The Bull Rankings model’s 86.2/100 quality‑growth score, with Growth as the strongest pillar, shows that the market already prizes its high‑margin, high‑growth trajectory, but the 49%/yr implied free‑cash‑flow growth from the reverse‑DCF is still below the 70.7% revenue pace—leaving room for a 1‑3 yr upside. The thesis rests on the sustained expansion of its compute‑and‑networking AI platform in data‑center and automotive markets.
Moat. NVDA’s dominance in the data‑center AI segment is cemented by its proprietary CUDA architecture and the deep integration of its GPUs with NVIDIA’s AI software stack, creating a high switching cost for enterprise customers. The company’s 63% profit margin reflects pricing power from being the sole supplier of high‑performance GPUs for both professional visualization and autonomous vehicle training, a niche that competitors cannot replicate quickly due to the required silicon‑software co‑design.
Risk. The bear case hinges on the 2.21 beta and a P/E of 32.5, indicating that the market is already pricing in significant upside; a slowdown in AI adoption or a competitive breakthrough in alternative accelerators could erode margins. A 0.07 debt‑to‑equity ratio is low, but the high beta means that a downturn in the tech cycle could disproportionately hurt NVDA’s valuation, especially if revenue growth dips below the 70.7% YoY rate.
Horizon. 1-3 yr $302.83 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $443.37 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $657.71 if current growth sustains into durable earnings power.
9. GDDY — GoDaddy Inc. · score 85.3
Software - Infrastructure · price $89.09 · 1Y $104.80 · 5Y $153.44 · 10Y $227.61
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 13.2x A · PEG 0.68 A-
Why now. The bull case hinges on GoDaddy’s Applications & Commerce suite—especially the high‑margin Websites + Marketing and Managed WordPress tools—that is fueling a resilient 7.4% YoY revenue growth while delivering a solid 17.8% profit margin and a free‑cash‑flow generation of $1.7 B. Coupled with a low PE of 13.2x and a PEG of 0.68, the business is trading at a discount to its growth, meaning the compounding engine of recurring SaaS subscriptions can keep accelerating earnings for years to come. The thesis rests on the continued expansion of the A&C segment’s subscription base, which should keep the free‑cash‑flow runway healthy and drive upside.
Moat. GoDaddy’s moat derives from its entrenched platform that bundles domain registration, website building, and e‑commerce tools into a single workflow, creating high switching costs for small‑business owners who have built their brand on the Core Platform. The integrated ecosystem locks in recurring revenue and limits competitors’ ability to poach customers without offering a comparable all‑in‑one solution.
Risk. The bear case centers on the modest growth rate—only 7.4% YoY—which is well below the sector’s high‑growth peers and may not sustain the implied -17% annual free‑cash‑flow growth baked into today’s price; any slowdown would expose the stock’s valuation compression risk. A P/E of 13.2, while low, still reflects expectations of continued margin expansion that could be derailed by rising competitive pressure in the website‑builder market. A breach of the 52‑week low around $71.59 would confirm the downside narrative.
Horizon. 1-3 yr $104.80 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $153.44 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $227.61 if current growth sustains into durable earnings power.
10. TTD — The Trade Desk, Inc. · score 85.3
Advertising Agencies · price $19.34 · 1Y $24.32 · 5Y $35.61 · 10Y $52.82
FCF $842m C+ · Rev +15.5% B+ · D/E 0.17 A- · P/E 22.0x B · PEG 0.86 B+
Why now. The Trade Desk’s platform dominance in programmatic CTV and video ads fuels a relentless revenue engine, delivering 15.5% YoY growth and a healthy 14.6% profit margin that translates into $842 m of free cash flow. Our Bull Rankings model rates the stock 85.3/100 on quality‑growth, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The reverse‑DCF shows the market is pricing in a -4% FCF growth trajectory—far below the actual growth rate—leaving ample upside if the business continues its current pace.
Moat. TTD’s unified buying platform spans CTV, video, display, audio and native formats, creating a high‑switching‑cost ecosystem for agencies and advertisers who rely on its data‑rich, real‑time optimization tools. This breadth drives pricing power, reflected in a 17.6% ROE, and shields the business from rivals who must rebuild comparable cross‑channel infrastructure.
Risk. The stock trades at a forward P/E of 22, well above many sector peers, while the Bull Rankings model flags Value as its weakest pillar, suggesting the market may be over‑paying for growth that could decelerate from the current 15.5% rate. A slowdown in CTV spend or a shift to rival platforms would compress margins and trigger a sell‑off, with the price falling back toward the 52‑week low of $16.70 as the first red flag.
Horizon. 1-3 yr $24.32 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $35.61 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $52.82 if current growth sustains into durable earnings power.
11. ADMA — ADMA Biologics, Inc. · score 84.5
Biotechnology · price $8.91 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 13.1x A- · PEG 0.67 A-
Why now. ADMA’s growth engine is anchored in its plasma‑derived IVIG franchise – BIVIGAM and ASCENIV – which command a 32.4% profit margin and fuel an 11% YoY revenue growth. The business’s ROE of 42.4% and a modest PE of 13.1x underscore a high‑quality, cash‑rich compounder that can reinvest earnings while buying back stock, delivering compounding earnings that our model flags as the strongest pillar. The thesis hinges on sustained IVIG demand and the ability to translate that into continued margin‑driven earnings growth.
Moat. ADMA controls the full plasma‑to‑product chain through its ADMA BioManufacturing and Plasma Collection Centers, creating a captive supply of high‑purity immunoglobulins that rivals cannot quickly replicate. This vertical integration yields pricing power in the primary humoral immunodeficiency market, reflected in a ROE above 40%, and entrenches long‑term contracts with hospitals and specialty pharmacies that lock in revenue streams.
Risk. The stock trades at a steep discount to its 52‑week high of $20.46, but the current price already embeds a reverse‑DCF implied free‑cash‑flow growth of only ~4% per year—far below the 11% revenue growth rate—suggesting the market is pricing in execution risk. A debt‑to‑equity of 1.11 adds leverage pressure, and any slowdown in plasma collection or regulatory setbacks to IVIG products would crush margins and confirm the bear case.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
12. ANIP — ANI Pharmaceuticals, Inc. · score 83.9
Drug Manufacturers - Specialty & Generic · price $79.20 · 1Y $110.00 · 5Y $161.05 · 10Y $238.91
FCF $191m C · Rev +37.0% A · D/E 1.12 C · P/E 20.3x B+ · PEG 0.46 A
Why now. ANI’s injectable portfolio, anchored by ILUVIEN and YUTIQ, is driving a 37% YoY revenue surge—backed by a 9.9% profit margin and $191 M free cash flow—and our Bull Rankings model assigns a Quality‑Growth score of 83.9, with Growth as the strongest pillar, indicating that the current $79.20 price already assumes aggressive expansion; the thesis rests on sustaining this specialty‑drug growth, which far outpaces the reverse‑DCF implied -8% FCF growth.
Moat. The company’s exclusive manufacturing of controlled‑substance injectables for specialty pharmacies, hospitals, and group purchasing organizations creates high switching costs, while a 16.3% ROE reflects pricing power derived from its niche, regulated market that competitors cannot replicate quickly.
Risk. A debt‑to‑equity of 1.12 signals leverage risk, and a 20.3× P/E suggests the market is pricing in aggressive growth; if revenue growth decelerates or margins compress, the $110 analyst target would be untenable, and a breach of the 52‑week low at $64.69 would confirm the bear case.
Horizon. 1-3 yr $110.00 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $161.05 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $238.91 if current growth sustains into durable earnings power.
13. EXLS — ExlService Holdings, Inc. · score 83.6
Information Technology Services · price $34.39 · 1Y $44.38 · 5Y $64.97 · 10Y $96.38
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 21.8x B+ · PEG 1.01 B+
Why now. ExlService’s AI‑driven claims management and underwriting support in the insurance sector is scaling at a 13.4% YoY revenue growth, a 21.8× P/E that still leaves room for margin expansion, and a 32.3% ROE that signals pricing power in a niche where data is king. The company’s free‑cash‑flow of $297 m fuels a buy‑back program that shrinks equity while earnings grow, positioning EXLS to compound returns as AI adoption deepens in underwriting and risk analytics. The thesis rests on the sustained 13.4% revenue growth and the company’s ability to convert that into higher margins through its AI‑enabled services.
Moat. ExlService’s moat is its AI‑powered analytics platform that bundles claims management, premium administration, and actuarial risk analytics for insurance carriers. This integrated suite creates high switching costs for clients, as migrating to a competitor would require re‑engineering complex data pipelines and retraining underwriting staff. The platform’s proprietary algorithms also give ExlService a cost advantage, enabling it to deliver services at lower marginal cost than new‑entry data vendors.
Risk. The bear case hinges on the fact that ExlService’s P/E of 21.8× is already premium relative to the sector, and its debt‑to‑equity of 0.57 could tighten if capital markets sour. A slowdown in AI adoption in the insurance market—say a 5% drop in revenue growth—would compress margins and erode the 32.3% ROE, breaking the buy‑back driven upside. A sharp decline in its core insurance client base would also hit the business, as the company’s revenue is concentrated in that segment.
Horizon. 1-3 yr $44.38 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $64.97 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.38 if current growth sustains into durable earnings power.
14. CARG — CarGurus, Inc. · score 82.9
Auto & Truck Dealerships · price $37.02 · 1Y $37.77 · 5Y $55.30 · 10Y $82.03
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B+ · P/E 19.5x B · PEG 1.10 B+
Why now. CarGurus’ Digital Deal platform is turning its massive shopper audience into a high‑margin, repeat‑purchase engine, driving revenue up 14% YoY while preserving a solid 15.9% profit margin. The Bull Rankings model rates the business a Quality‑growth score of 82.9—its strongest pillar, Quality, reflects a ROE of 62.9% that outpaces peers, confirming pricing power in the dealer‑subscription ecosystem. The thesis hinges on the continued compounding of Digital Deal adoption, which should keep growth above the zero‑percent FCF growth implied by the reverse‑DCF.
Moat. The platform’s integrated suite—Dealer Subscription, Advertising, and Digital Deal—locks dealers into a data‑rich, lead‑generation loop that is costly to replicate, giving CarGurus a network advantage and enabling it to command premium pricing, evident in its 62.9% ROE. This sticky dealer relationship translates into high‑margin cash flows that fund buybacks, reinforcing shareholder value.
Risk. Bears point to a P/E of 19.5× and a beta of 1.17, suggesting the stock is priced for continued acceleration despite a modest revenue growth runway; any slowdown below the 14% FY growth rate would expose the valuation gap and pressure the share price toward the 52‑week low of $26.39. A rise in debt‑to‑equity toward 1.0 would also strain the balance sheet, confirming the downside if leverage creeps higher.
Horizon. 1-3 yr $37.77 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $55.30 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $82.03 if current growth sustains into durable earnings power.
15. RMD — ResMed Inc. · score 82.4
Medical Instruments & Supplies · price $223.14 · 1Y $248.53 · 5Y $363.88 · 10Y $539.79
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 21.5x B+ · PEG 1.26 B
Why now. Medical Instruments & Supplies · market cap $32.4b. Down 24% from 52-week high of $293.81 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $248.53 (implying +11% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $248.53 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $363.88 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $539.79 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 82.1
Information Technology Services · price $112.06 · 1Y $133.94 · 5Y $169.10 · 10Y $216.86
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 16.1x A- · PEG 0.54 A-
Why now. Information Technology Services · market cap $5.9b. Down 50% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.54 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $133.94 (implying +20% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 50% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $133.94 (analyst consensus (n=17)) — multiple re-rating thesis requires a catalyst. 5 yr $169.10 at ~9% CAGR — dividend + buyback compounding. 10 yr $216.86 if the moat survives secular pressure.
17. META — Meta Platforms, Inc. · score 82.1
Internet Content & Information · price $587.94 · 1Y $759.41 · 5Y $958.73 · 10Y $1,230
FCF $48.3b A · Rev +26.2% A- · D/E 0.43 B+ · P/E 22.1x B · PEG 0.83 B+
Why now. Internet Content & Information · market cap $1.5T. Down 26% from 52-week high of $796.25 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. PEG 0.83 — paying under fair value for the growth rate. 57 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $759.41 (implying +29% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.5T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $759.41 (analyst consensus (n=57)) — multiple re-rating thesis requires a catalyst. 5 yr $958.73 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,230 if the moat survives secular pressure.
18. CPAY — Corpay, Inc. · score 81.4
Software - Infrastructure · price $396.52 · 1Y $396.21 · 5Y $500.21 · 10Y $641.51
FCF $1.3b C+ · Rev +18.3% B+ · D/E 2.71 D · P/E 23.7x B+ · PEG 0.92 B+
Why now. Software - Infrastructure · market cap $25.9b. Trading near 52-week high of $398.31 — momentum setup, limited technical margin of safety. Revenue growing +18%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $396.21 (implying -0% upside).
Moat. Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 34% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 111% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.71 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $396.21 (analyst consensus (n=14)) — multiple re-rating thesis requires a catalyst. 5 yr $500.21 at ~5% CAGR — dividend + buyback compounding. 10 yr $641.51 if the moat survives secular pressure.
19. VEEV — Veeva Systems Inc. · score 80.3
Health Information Services · price $211.86 · 1Y $244.14 · 5Y $357.45 · 10Y $530.25
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 37.6x C+ · PEG 0.92 B+
Why now. Health Information Services · market cap $34.4b. Down 32% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $244.14 (implying +15% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 38x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 10.4x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $244.14 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $357.45 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $530.25 if current growth sustains into durable earnings power.
20. ACN — Accenture plc · score 79.8
Information Technology Services · price $170.43 · 1Y $178.89 · 5Y $225.85 · 10Y $289.64
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 13.6x A- · PEG 1.21 B
Why now. Information Technology Services · market cap $104.3b. Down 41% from 52-week high of $291.09 — deep drawdown territory. 25 sell-side analysts rate this a Buy with a mean 1-yr target of $178.89 (implying +5% upside).
Moat. ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 162% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $104.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $178.89 (analyst consensus (n=25)) — multiple re-rating thesis requires a catalyst. 5 yr $225.85 at ~6% CAGR — dividend + buyback compounding. 10 yr $289.64 if the moat survives secular pressure.
21. APP — AppLovin Corporation · score 79.7
Advertising Agencies · price $419.70 · 1Y $656.20 · 5Y $960.74 · 10Y $1,425
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 36.5x C+ · PEG 1.09 B+
Why now. Advertising Agencies · market cap $141.0b. Down 44% from 52-week high of $745.61 — deep drawdown territory. Revenue growing +66% — in hypergrowth territory. 30 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $656.20 (implying +56% upside).
Moat. Net margin 64% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $141.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 44% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.53 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $656.20 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $960.74 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,425 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 79.6
Footwear & Accessories · price $99.87 · 1Y $122.81 · 5Y $155.04 · 10Y $198.84
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 14.2x A- · PEG 1.19 B+
Why now. Footwear & Accessories · market cap $13.6b. Down 20% from 52-week high of $125.45 — deep drawdown territory. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $122.81 (implying +23% upside).
Moat. Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 44% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 110% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $155.04 at ~9% CAGR — dividend + buyback compounding. 10 yr $198.84 if the moat survives secular pressure.
23. DXCM — DexCom, Inc. · score 79.5
Medical Devices · price $86.94 · 1Y $93.44 · 5Y $136.81 · 10Y $202.94
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.4x C+ · PEG 1.56 C+
Why now. Medical Devices · market cap $32.8b. Trading near 52-week high of $87.83 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $93.44 (implying +7% upside).
Moat. Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $93.44 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $136.81 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $202.94 if current growth sustains into durable earnings power.
24. MELI — MercadoLibre, Inc. · score 79.3
Internet Retail · price $1888.50 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 49.2x D · PEG 1.16 B+
Why now. Internet Retail · market cap $95.7b. Down 26% from 52-week high of $2548.50 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,215 (implying +17% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $95.7b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Trailing P/E 49x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
25. PODD — Insulet Corporation · score 79
Medical Devices · price $166.82 · 1Y $235.54 · 5Y $344.86 · 10Y $511.57
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 39.0x C+ · PEG 1.46 B
Why now. Medical Devices · market cap $11.6b. Down 53% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +32% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $235.54 (implying +41% upside).
Moat. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 53% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $235.54 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $344.86 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $511.57 if current growth sustains into durable earnings power.
26. VRT — Vertiv Holdings Co · score 78
Electrical Equipment & Parts · price $269.93 · 1Y $337.50 · 5Y $494.13 · 10Y $733.01
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 61.1x D · PEG 1.14 B+
Why now. Electrical Equipment & Parts · market cap $103.9b. Down 29% from 52-week high of $379.94 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. 26 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $337.50 (implying +25% upside).
Moat. Net margin 15% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 169% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trailing P/E 61.1x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Beta 2.08 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $337.50 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $494.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $733.01 if current growth sustains into durable earnings power.
27. FIVE — Five Below, Inc. · score 77.7
Specialty Retail · price $222.30 · 1Y $260.48 · 5Y $328.85 · 10Y $421.74
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 28.0x C+ · PEG 0.98 B+
Why now. Specialty Retail · market cap $12.3b. 12% off the 52-week high of $251.63. Revenue growing +26% — in hypergrowth territory. PEG 0.98 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $260.48 (implying +17% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $260.48 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $328.85 at ~8% CAGR — dividend + buyback compounding. 10 yr $421.74 if the moat survives secular pressure.
28. EME — EMCOR Group, Inc. · score 76.5
Engineering & Construction · price $819.88 · 1Y $1,044 · 5Y $1,318 · 10Y $1,691
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 25.5x B · PEG 0.42 A
Why now. Engineering & Construction · market cap $36.2b. 14% off the 52-week high of $951.96. Revenue growing +19%, comfortably above the S&P median. PEG 0.42 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,044 (implying +27% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,044 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,318 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,691 if the moat survives secular pressure.
29. NFLX — Netflix, Inc. · score 75.9
Entertainment · price $73.57 · 1Y $94.33 · 5Y $138.10 · 10Y $204.87
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B · P/E 23.1x B · PEG 1.61 C+
Why now. Entertainment · market cap $306.3b. Down 42% from 52-week high of $126.71 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 45 sell-side analysts rate this a Buy with a mean 1-yr target of $94.33 (implying +28% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 45% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $306.3b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.51 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $94.33 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $138.10 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $204.87 if current growth sustains into durable earnings power.
30. CCK — Crown Holdings, Inc. · score 75.4
Packaging & Containers · price $121.66 · 1Y $136.57 · 5Y $172.42 · 10Y $221.12
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 17.5x B+ · PEG 0.64 A-
Why now. Packaging & Containers · market cap $13.2b. Trading near 52-week high of $121.90 — momentum setup, limited technical margin of safety. Revenue growing +10%, comfortably above the S&P median. PEG 0.64 — paying under fair value for the growth rate. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $136.57 (implying +12% upside).
Moat. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 153% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — multiple re-rating thesis requires a catalyst. 5 yr $172.42 at ~7% CAGR — dividend + buyback compounding. 10 yr $221.12 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.